ZimVie announces a study indicating its dental implants may reduce peri-implant infection risk compared to competitors.
Quiver AI Summary
ZimVie Inc. has announced the publication of a scientific study indicating that the surface texture of its premium dental implants may reduce the risk of peri-implant infections compared to other brands. The study, featured in the Journal of Biomedical Materials Research, examines ZimVie's dual acid-etched coronal surface technology on the T3® PRO and TSX® Implants, showing that these surfaces promote lower bacterial adhesion similar to smooth machined surfaces while maintaining crestal bone levels. The research is significant as peri-implantitis rates have been rising, and ZimVie's innovative designs aim to enhance patient safety and implant longevity. The company, headquartered in Palm Beach Gardens, is dedicated to advancing dental solutions and improving patient outcomes in tooth replacement and restoration.
Potential Positives
- The publication of a scientific study in a leading journal highlights ZimVie’s commitment to advancing dental implant technology and supports their market positioning as a leader in the dental implant field.
- The study's findings that ZimVie’s implants may lower the risk of peri-implant infections enhance the perceived safety and effectiveness of their products, potentially attracting more customers and increasing sales.
- Innovative features of ZimVie’s TSX and T3 PRO implants, such as improved primary stability and crestal bone maintenance, reinforce the company's dedication to quality and patient safety, further establishing confidence among dental professionals.
Potential Negatives
- The press release emphasizes the increasing prevalence of peri-implant infections, suggesting a growing concern within the industry that may negatively affect consumer confidence in dental implants.
- Despite showcasing the technical advancements of their implants, the need for improved solutions indicates that previous products may not have effectively addressed infection risks.
- The use of legal cautionary statements may raise concerns among investors about the company's future performance and the reliability of their forward-looking claims.
FAQ
What does ZimVie's new study reveal about implant surface texture?
The study shows ZimVie's implant surface texture may lower the risk of peri-implant infections compared to other implants.
Where was the ZimVie implant study published?
The study was published in the Journal of Biomedical Materials Research, a top journal in biological and medical sciences.
What are TSX and T3 PRO Implants?
TSX and T3 PRO Implants are advanced dental implants designed for stability, durability, and peri-implant health through innovative surface technology.
What is the issue of peri-implantitis?
Peri-implantitis refers to inflammation around dental implants, which can lead to bone loss and jeopardize implant success.
How does ZimVie support dental restoration procedures?
ZimVie provides a comprehensive portfolio of dental products, including implants and digital workflow solutions to enhance dental restoration and tooth replacement.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ZIMV Insider Trading Activity
$ZIMV insiders have traded $ZIMV stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $ZIMV stock by insiders over the last 6 months:
- CAPITAL MANAGEMENT LP CAMBER sold 525,000 shares for an estimated $9,299,377
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ZIMV Hedge Fund Activity
We have seen 72 institutional investors add shares of $ZIMV stock to their portfolio, and 122 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- EVERSEPT PARTNERS, LP added 1,303,121 shares (+169.8%) to their portfolio in Q3 2024, for an estimated $20,680,530
- DIVISADERO STREET CAPITAL MANAGEMENT, LP removed 1,059,900 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $16,820,613
- MORGAN STANLEY added 869,187 shares (+425.4%) to their portfolio in Q3 2024, for an estimated $13,793,997
- MILLENNIUM MANAGEMENT LLC removed 614,753 shares (-45.1%) from their portfolio in Q3 2024, for an estimated $9,756,130
- CAMBER CAPITAL MANAGEMENT LP removed 525,000 shares (-16.2%) from their portfolio in Q3 2024, for an estimated $8,331,750
- SOLAS CAPITAL MANAGEMENT, LLC added 384,655 shares (+2506.7%) to their portfolio in Q3 2024, for an estimated $6,104,474
- J. GOLDMAN & CO LP removed 293,448 shares (-35.5%) from their portfolio in Q3 2024, for an estimated $4,657,019
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
PALM BEACH GARDENS, Fla., Jan. 30, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental implant market, today announced the publication of a detailed scientific study demonstrating the surface texture of ZimVie’s premium implants may help to lower the risk of peri-implant infections when compared to other commercially available implants.
The
study
, titled “The Role of Implant Coronal Surface Properties on Early Adhesion of
Streptococcus Oralis
—An In Vitro Comparative Study,” has been published in the
Journal of Biomedical Materials Research
, a leading journal in the field of biological and medical sciences. The study evaluated the innovative dual acid-etched coronal surface technology of ZimVie’s T3
®
PRO and TSX
®
Implants against other leading implant brands.
In dental implantology, rough surfaces at the top of the implant, designed to maintain crestal bone levels, may also promote bacterial adhesion. This potentially leads to soft tissue inflammation and peri-implant bone loss, jeopardizing long-term implant success. The new data reveals a critical threshold roughness, above which bacterial adhesion increases significantly, while below that, bacterial adhesion profiles remain comparable to smooth machined surfaces. ZimVie’s implants’ coronal surfaces, DAE and Osseotite
®
, have been engineered around this threshold. These surfaces not only exhibit bacterial adhesion levels comparable to machined surfaces but also demonstrate crestal bone maintenance akin to rougher surfaces.*
“The prevalence of peri-implant mucositis (inflammation) and peri-implantitis has been on the rise in recent decades,” said Hai Bo Wen, Research Director at ZimVie. “We have always been committed to the highest standards of quality and patient safety and are proud that ZimVie’s Contemporary Hybrid Surface technologies have demonstrated success in helping mitigate this concern in today’s dental implantology field.”
About TSX Implants
Launched in 2022, TSX Implants are designed for immediate extraction and standard loading protocols as well as placement predictability and primary stability in soft and dense bone. The Implant incorporates features with more than two decades of real-world, clinical data to deliver peri-implant health, crestal bone maintenance, long-term osseointegration, and prosthetic stability,* including the Contemporary Hybrid Surface combination with coronal DAE. Integrated with ZimVie’s end-to-end digital workflows and engineered with surgical and restorative versatility, the TSX Implant furthers ZimVie’s commitment to simplify procedures and optimize practice protocols.
About T3 PRO Implants
Launched in 2022, the T3 PRO Implant’s advanced design delivers high primary stability and allows for immediate function. T3 PRO has a hybrid surface featuring the proprietary Osseotite surface on the implant collar, as well as a rougher grit-blasted implant body. Not only have multiple long-term, independent clinical studies on the proprietary Osseotite surface demonstrated safety and performance,* they have also demonstrated the effect of this surface in preserving crestal bone. This Contemporary Hybrid Surface of T3 PRO along with the optional integrated platform switching design has also been shown to provide early and long-term peri-implant bone support.
* References on file at ZimVie.
About ZimVie
ZimVie is a global life sciences leader in the dental market that develops, manufactures, and delivers a comprehensive portfolio of products and solutions designed to support dental tooth replacement and restoration procedures. From its headquarters in Palm Beach Gardens, Florida, and additional facilities around the globe, ZimVie works to improve smiles, function, and confidence in daily life by offering comprehensive tooth replacement solutions, including trusted dental implants, biomaterials, and digital workflow solutions. As a worldwide leader in this space, ZimVie is committed to advancing clinical science and technology foundational to restoring daily life. For more information about ZimVie, please visit us at
www.ZimVie.com
. Follow @ZimVie on
Twitter
,
Facebook
,
LinkedIn
, or
Instagram
.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning ZimVie’s expectations, plans, prospects, and product and service offerings, including new product launches and potential clinical successes. Such statements are based upon the current beliefs, expectations, and assumptions of management and are subject to significant risks, uncertainties, and changes in circumstances that could cause actual outcomes and results to differ materially from the forward-looking statements. For a list and description of some of such risks and uncertainties, see ZimVie’s periodic reports filed with the U.S. Securities and Exchange Commission (SEC). These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in ZimVie’s filings with the SEC. Forward-looking statements speak only as of the date they are made, and ZimVie disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Readers of this press release are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary note is applicable to all forward-looking statements contained in this press release.
Media Contact Information:
ZimVie
Grace Flowers •
Grace.Flowers@ZimVie.com
(561) 319-6130
Investor Contact Information:
Gilmartin Group LLC
Webb Campbell •
Webb@gilmartinir.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
